REALYSA aims to constitute a platform for innovative and ambitious research projects. To date, the REALYSA data and collection of biological samples have been and will used for the following research projects.
Last update: 22/MAY/2024.
If you would like to submit a research project with the cohort, you will find more information here.
REA-GIP STUDY: REPRESENTATIVENESS OF THE REAL-LIFE REALYSA COHORT OF POITOU_CHARENTES (POITIERS-NIORT) COMPARED TO A POPULATION COHORT FROM THE POITOU-CHARENTES GENERAL CANCER REGISTRY
SynthEID study: developing a method for constituting a reference group of patients aged 80 years and over with a diffuse large B-cell lymphoma
SENIOR IPI: Prognostic score for patients with diffuse large B-cell lymphomas over 80 years of age
SYNTH-L study: developing a method for constituting a reference group of patients with Hodgkin lymphoma
ELKIN study: Identifying the biological reasons for treatment failures for Hodgkin’s lymphoma in elderly patients
ANTICANCER study: links between cancer and immune aging
ESCAPE study: Impact of a biomarker on the evolution of T-cell lymphomas
REALMA – Characteristics and Management of Patients with Marginal Zone Lymphoma
MCL_TOUR : Description and management of mantle cell lymphomas
FRENCH CONNECT study – Study of tumor DNA for the management of lymphomas
Description and management of diffuse lymphomas receiving a 2nd line of therapy
Description et prise en charge des lymphomes diffus recevant un traitement de 3ème ligne
COMPARISON OF PATIENTS INCLUDED AND NOT INCLUDED IN REALYSA AT LYON-SUD HOSPITAL
Description and care pathway for people over 60 years of age with diffuse large B-cell lymphoma
PELYCANO study – impact of pesticide exposure in patients with diffuse large B-cell lymphoma
Research project on anaplastic large cell lymphoma
Use of Brentuximab Vedotin before transplant – HL
Brentuximab Vedotin Usage Report 2021 and 2022
REALY-QoL – Quality of Life of patients with lymphoma in France
Research project on T-cell lymphoma
POLARYSA – a study on diffuse large B-cell lymphoma
Brentuximab Vedotin Usage Report 2019 and 2020